[
  {
    "ts": null,
    "headline": "NVST vs. ABT: Which Stock Is the Better Value Option?",
    "summary": "NVST vs. ABT: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=f896b35b00b1eb95200da66e604744470752e3a9e7415aca093a14c4c7543eca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754581203,
      "headline": "NVST vs. ABT: Which Stock Is the Better Value Option?",
      "id": 136263435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "NVST vs. ABT: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=f896b35b00b1eb95200da66e604744470752e3a9e7415aca093a14c4c7543eca"
    }
  },
  {
    "ts": null,
    "headline": "Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma",
    "summary": "The global influenza vaccine market is on a growth trajectory, driven by heightened awareness about vaccination's role in preventing contagious diseases like influenza. In light of recent pandemics, flu vaccination demand is surging, projected to climb from USD 8.96 billion in 2024 to USD 13.32 billion by 2030, at a CAGR of 7%. Rising geriatric populations, government support, and public health campaigns fuel this expansion. Dominant market segments include quadrivalent vaccines, inactivated typ",
    "url": "https://finnhub.io/api/news?id=55c7cc77d1fd20de5684daa8ba9a18267a9e8f07b6b81697e00ce172515607a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754576160,
      "headline": "Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma",
      "id": 136248796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The global influenza vaccine market is on a growth trajectory, driven by heightened awareness about vaccination's role in preventing contagious diseases like influenza. In light of recent pandemics, flu vaccination demand is surging, projected to climb from USD 8.96 billion in 2024 to USD 13.32 billion by 2030, at a CAGR of 7%. Rising geriatric populations, government support, and public health campaigns fuel this expansion. Dominant market segments include quadrivalent vaccines, inactivated typ",
      "url": "https://finnhub.io/api/news?id=55c7cc77d1fd20de5684daa8ba9a18267a9e8f07b6b81697e00ce172515607a7"
    }
  },
  {
    "ts": null,
    "headline": "Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market",
    "summary": "With a new CEO taking over in 2026, Dexcom aims to stay ahead of its CGM competitors through a combination of innovation and product market expansion.",
    "url": "https://finnhub.io/api/news?id=83cecc1774b44fb7455d235c73fee7449f9e6a3334d32296a7818691bfc027df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754559547,
      "headline": "Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market",
      "id": 136246234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "With a new CEO taking over in 2026, Dexcom aims to stay ahead of its CGM competitors through a combination of innovation and product market expansion.",
      "url": "https://finnhub.io/api/news?id=83cecc1774b44fb7455d235c73fee7449f9e6a3334d32296a7818691bfc027df"
    }
  }
]